Inventor · disambiguated record
Dale Porter
Also filed as: PORTER DALE · PORTER DALE A · PORTER DALE ALAN · PORTER JR DALE A
12 granted patents·9 pending applications·12 citations·filing 2002–2022
84Inventor score
Files withCEDILLA THERAPEUTICS INC5DANA FARBER CANCER INST INC5NOVARTIS AG5SERVIER LAB2FIRESTONE BRANT G1
Top patents by PatentIndex Score
21 records- 0178US10130629B2Pharmaceutical combinationsNOVARTIS AG·Filed 2016·Granted Nov 20, 2018·3 cites·7 claims
- 0275US6815166B2HIN-1, a tumor suppressor geneDANA FARBER CANCER INST INC·Filed 2002·Granted Nov 9, 2004·6 cites·12 claims
- 0370US7608696B2IBC-1 (invasive breast cancer-1), a putative oncogene amplified in breast cancerDANA FARBER CANCER INST INC·Filed 2004·Granted Oct 27, 2009·1 cites·16 claims
- 0467US8110370B2IBC-1 (Invasive Breast Cancer-1), a putative oncogene amplified in breast cancerPOLYAK KORNELIA·Filed 2009·Granted Feb 7, 2012·0 cites·25 claims
- 0567US8034561B2HIN-1, a tumor suppressor geneDANA FARBER CANCER INST INC·Filed 2009·Granted Oct 11, 2011·0 cites·11 claims
- 0666US9446043B2Pharmaceutical combinationsNOVARTIS AG·Filed 2013·Granted Sep 20, 2016·2 cites·19 claims
- 0764US7625715B2HIN-1, a tumor suppressor geneDANA FARBER CANCER INST INC·Filed 2004·Granted Dec 1, 2009·0 cites·26 claims
- 0856US10507201B2Use of ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitorsNOVARTIS AG·Filed 2019·Granted Dec 17, 2019·0 cites·17 claims
- 0952US2007054271A1Gene expression in breast cancerDANA FARBER CANCER INST INC·Filed 2004·Application pending·0 cites
- 1049US2023115350A1Tead inhibitors and uses thereofCEDILLA THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1149US2023053649A1Tead inhibitors and uses thereofCEDILLA THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1248US12053459B2CDK2 inhibitors and methods of using the sameCEDILLA THERAPEUTICS INC·Filed 2022·Granted Aug 6, 2024·0 cites·23 claims
- 1348US2023098872A1Tead inhibitors and uses thereofCEDILLA THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1446US2018185341A1Use of ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitorsNOVARTIS AG·Filed 2015·Application pending·0 cites
- 1545US12065445B2CDK2 inhibitors and methods of using the sameCEDILLA THERAPEUTICS INC·Filed 2022·Granted Aug 20, 2024·0 cites·38 claims
- 1645US9353419B2Biomarkers for IAP inhibitor therapyPORTER DALE·Filed 2013·Granted May 31, 2016·0 cites·26 claims
- 1740US2010316573A1Organic CompoundsGAITHER LARRY ALEXANDER·Filed 2007·Application pending·0 cites
- 1836US2017304313A1Therapeutic Combination For The Treatment Of CancerNOVARTIS AG·Filed 2015·Application pending·0 cites
- 1935US10765680B2Combination of a MCL-1 inhibitor and a taxane compound, uses and pharmaceutical compositions thereofSERVIER LAB·Filed 2018·Granted Sep 8, 2020·0 cites·16 claims
- 2033US2012196793A1Biomarkers for iap inhibitor compoundsFIRESTONE BRANT G·Filed 2010·Application pending·0 cites
- 2130US2019240225A1Combination of a bcl-2 inhibitor and a mcl-1 inhibitor, uses and pharmaceutical compositions thereofSERVIER LAB·Filed 2017·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Dale Porter files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →